Diabetes & Endocrinology
Latest news
532 articles · 20 / page
Impact of a Multifactorial Diet on ApoC-III, Ectopic Fat, and Beta Cell Function in Type 2 Diabetes: Insights from the MEDEA Study
The MEDEA randomized trial demonstrated that a multifactorial diet reduces plasma ApoC-III, correlates with decreased liver and pancreatic fat, and improves beta cell function in type 2 diabetes compared to a MUFA-rich diet.
Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact
A prespecified subanalysis of the PACMAN-HF trial demonstrates that individualized nutritional interventions in chronic heart failure patients at risk of malnutrition improve nutritional status and functional capacity but do not significant
Prepregnancy Time-Restricted Eating and Exercise Training Do Not Improve Glycaemic Control in High-Risk Gestational Diabetes: Insights from the BEFORE THE BEGINNING Trial
A randomized trial investigating time-restricted eating and exercise before and during pregnancy found no significant improvement in glucose tolerance at 28 weeks gestation among individuals at elevated risk of gestational diabetes.
Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial
A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent
Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial
The MeMeMe randomized trial shows that metformin 1,700 mg/day effectively prevents type 2 diabetes in metabolic syndrome patients, independent of Mediterranean diet adherence, with implications for age-related disease prevention.
Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.
Mobile Text Messaging Enhances Glycemic and Blood Pressure Control in Adults with Uncontrolled Type 2 Diabetes
A randomized trial in China shows that a 12-month mobile message-based intervention modestly improves HbA1c and systolic blood pressure in patients with uncontrolled type 2 diabetes, supporting mHealth strategies to manage cardiovascular ri
Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of Randomized Controlled Trial Evidence and Clinical Implications
Automated insulin delivery (AID) significantly improves glycemic control in insulin-treated type 2 diabetes, demonstrating greater HbA1c reduction and increased time in target glucose range compared to traditional insulin delivery methods.
Advancing Type 1 Diabetes Care: Stem Cell-Derived Islet Therapy with Zimislecel
Zimislecel, an allogeneic stem cell-derived islet-cell therapy, demonstrates promising safety and efficacy for type 1 diabetes, restoring physiologic islet function and enabling insulin independence in a phase 1-2 trial.
The Most Cost-Effective Exercise Discovered: Just 4 Minutes Daily Cuts Heart Disease Risk by 45%
A new study reveals that short bursts of vigorous ‘snack exercise’ totaling as little as 3–4 minutes daily can significantly reduce cardiovascular disease risk, especially among women.
Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes
Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.
Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial
The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.
Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity
A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerabi
Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial
The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.
Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial
The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or
Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy
Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.
Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications
Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.
What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care
A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.
Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis
In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF i
Targeted Reduction of Sitting Time Versus Increased Sit-to-Stand Transitions: Effects on Blood Pressure and Glucose Regulation in Postmenopausal Women
A 3-month randomized trial in overweight postmenopausal women found that increasing sit-to-stand transitions significantly reduces diastolic blood pressure, while reducing total sitting time alone does not improve blood pressure or glucoreg
Browse by specialty
Open language-specific specialty feeds and department pages.